Related Experiment Video

Updated: Feb 21, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.2K

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential

Melissa Bersanelli1, Sebastiano Buti2

  • 1University Hospital of Parma, Medical Oncology Unit, Via Gramsci 14, 43126, Parma (PR), Italy.

Therapeutic Advances in Medical Oncology
|October 5, 2017
PubMed

Insights

Cabozantinib shows excellent outcomes for metastatic renal cell carcinoma (mRCC) treatment, including response rate and survival. Its safety is acceptable, suggesting a valuable role in mRCC therapy.

Area of Science:

  • Oncology
  • Medical Science

Background:

  • Immunotherapy has transformed metastatic renal cell carcinoma (mRCC) treatment.
  • Tyrosine kinase inhibitors (TKIs) are often overlooked in favor of immune checkpoint blockade.
  • Cabozantinib, a TKI, warrants specific consideration for mRCC management.

Purpose of the Study:

  • To re-evaluate the efficacy and safety of cabozantinib in mRCC treatment.
  • To highlight cabozantinib's specific benefits beyond general TKI classifications.
  • To explore potential mechanisms and future applications of cabozantinib.

Main Methods:

  • Review of clinical outcomes associated with cabozantinib in mRCC.
  • Comparison of cabozantinib's safety profile with other TKIs.
  • Consideration of ongoing research into combination therapies.

Main Results:

  • Cabozantinib demonstrates outstanding response rates, progression-free survival, and overall survival in mRCC.
  • The drug offers a quick time to treatment response.
  • Its safety profile is acceptable, with discontinuation rates comparable to other TKIs.

Conclusions:

  • Cabozantinib is a highly effective treatment option for mRCC, offering significant clinical benefits.
  • Further research is needed to elucidate its precise mechanism of action and optimize its use.
  • Strategic sequencing of cabozantinib, potentially with immunotherapy, holds promise for future mRCC treatment paradigms.
Keywords:
cabozantinibkidney cancer treatmentmetastatic renal cell carcinomarenal cell carcinomatyrosine kinase inhibitors

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.5K
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.3K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K